| |
| |
|
| Insider
Information: |
Foehr Matthew W |
| Relationship: |
President and CEO, Dir... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
3,948,737 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$36,130,555 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,948,737 |
|
|
| Total
Value |
$36,130,555 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
8
|
0
|
| Stock
price went down : |
5
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
1.6
|
-4.0
|
| Percentage
Gain/Loss : |
 35.5%
|
 -89.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
162,187 |
2011-04-18 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2022-05-02 |
111,250 |
2015-05-04 |
0 |
Premium* |
|
|
Qualigen Therapeutics Inc |
QLGN |
Director |
2020-04-10 |
138,635 |
2015-06-24 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
President and CEO, Dir... |
2024-05-24 |
3,536,665 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
136 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2022-05-13 |
4 |
B |
$82.76 |
$206,910 |
D/D |
2,500 |
173,354 |
2.74 |
% |
|
| OABI |
OmniAb, Inc |
President & CEO |
• • – |
2022-11-09 |
4 |
B |
$2.76 |
$276,160 |
D/D |
100,000 |
1,405,350 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President & CEO |
• • – |
2022-11-30 |
4 |
B |
$3.39 |
$1,016,340 |
D/D |
300,000 |
1,705,350 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President & CEO |
• • – |
2022-12-12 |
4 |
B |
$3.77 |
$564,765 |
D/D |
150,000 |
1,838,084 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-05-12 |
4 |
B |
$3.40 |
$1,496,000 |
D/D |
440,000 |
2,438,414 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-06-09 |
4 |
B |
$4.52 |
$519,800 |
D/D |
115,000 |
2,574,009 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2023-08-14 |
4 |
B |
$5.48 |
$246,600 |
D/D |
45,000 |
2,332,919 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2023-11-10 |
4 |
B |
$4.27 |
$405,517 |
D/D |
95,000 |
2,427,919 |
0.01 |
% |
|
| OABI |
OmniAb, Inc |
Chief Executive Officer |
• • – |
2023-12-12 |
4 |
B |
$5.05 |
$1,010,000 |
D/D |
200,000 |
2,645,442 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2024-03-22 |
4 |
B |
$5.19 |
$1,167,750 |
D/D |
225,000 |
2,908,803 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2024-05-24 |
4 |
B |
$4.42 |
$1,059,840 |
D/D |
240,000 |
3,536,665 |
2.81 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-02-15 |
4 |
D |
$85.97 |
$141,163 |
D/D |
(1,642) |
76,662 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-15 |
4 |
D |
$104.28 |
$246,831 |
D/D |
(2,367) |
80,670 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-24 |
4 |
D |
$100.38 |
$274,339 |
D/D |
(2,733) |
83,176 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-12-28 |
4 |
D |
$138.66 |
$411,959 |
D/D |
(2,971) |
98,494 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-02-15 |
4 |
D |
$157.18 |
$575,750 |
D/D |
(3,663) |
94,831 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-03-06 |
4 |
D |
$165.87 |
$241,673 |
D/D |
(1,457) |
101,201 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-01-23 |
4 |
D |
$111.78 |
$287,051 |
D/D |
(2,568) |
118,081 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-02-15 |
4 |
D |
$120.86 |
$341,550 |
D/D |
(2,826) |
122,727 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-12-20 |
4 |
D |
$105.87 |
$386,849 |
D/D |
(3,654) |
148,337 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-15 |
4 |
D |
$97.23 |
$241,714 |
D/D |
(2,486) |
153,743 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-01-25 |
4 |
D |
$156.01 |
$518,733 |
D/D |
(3,325) |
160,603 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2021-02-15 |
4 |
D |
$172.46 |
$534,281 |
D/D |
(3,098) |
165,100 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2022-01-26 |
4 |
D |
$113.68 |
$582,610 |
D/D |
(5,125) |
174,400 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2022-02-15 |
4 |
D |
$123.68 |
$438,569 |
D/D |
(3,546) |
170,854 |
0 |
- |
|
136 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
